De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

2019189 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 6, Issue 7, pp. e375-e383

Field-Weighted Citation Impact: 16.38